CClinicalTrials.gg
CompletedNCT03304938LavenAromDMUpdated Apr 8, 2019

Lavender Aromatherapy on Sleep Quality and Metabolic Parameters of Type 2 Diabetic Patients With Insomnia

An interventional study of Lavender Oil and Placebos in Diabetes Mellitus, Type 2 and Sleep Disturbance, sponsored by Shiraz University of Medical Sciences. Completed at 2 sites in Iran, Islamic Republic of. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-04-08.

Sponsored by Shiraz University of Medical Sciences · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Study summary

This study is designed as cross-over double-blind placebo-controlled randomized clinical trial that 40 diabetic patients with sleep disorder with the inclusion criteria will enter into the study and randomly assign to first intervention and first placebo groups.The primary outcomes are change in sleep disorder and metabolic parameters that will be evaluated at the end of the study.

Read the detailed description

Considering the high prevalence of sleep disturbance in diabetic patients and the effectiveness of lavender in treatment of sleep disorders in this study the efficacy of Lavender aromatherapy in sleep disorder and metabolic parameters in diabetic patients will be investigated. This study is designed as cross-over double-blind placebo-controlled randomized clinical trial that 40 diabetic patients with sleep disorder with the inclusion criteria will enter into the study and randomly assign to first intervention and first placebo groups.The primary outcomes are change in sleep disorder and metabolic parameters that will be evaluated at the end of the study.

02

Conditions studied

  • Diabetes Mellitus, Type 2
  • Sleep Disturbance
03

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diabetes mellitus type 2
  • Age between 25-65 years old
  • Fasting Blood Sugar between 70-130
  • 2 hour post prandial glucose less than 180.
  • HbA1C less than 7
  • Sleep disorder according to pittsburgh Insomnia Rating Scale more than 5.

Exclusion criteria

Exclusion Criteria:

  • Any systemic illnesses
  • Use of sedative or antidepressant drugs
  • Pregnancy
  • Lactation
  • History of allergic reaction to Lavender
  • History of allergic rhinitis, asthma and respiratory disorders
  • Anosmia
  • Headache that start with smell
  • Cigarette smocking or substance abuse
  • Hospitalization or surgery within 1 months ago.
  • Work shift
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    Lavender oil

    Drug: Lavender Oil

  • Placebo comparator
    vehicle (Almond oil)

    Drug: Placebos

Interventions

  • DrugLavender Oil

    The intervention group pour 3 drops of Lavender essential oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks

  • DrugPlacebos

    The placebo group pour 3 drops of Almond oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks

05

What researchers measure

Primary outcomes

  1. Pittsburgh Insomnia Rating Scale

    evaluate the sleep disorder with Pittsburgh Insomnia Rating Scale

    Time frame: 4 weeks

Secondary outcomes

  1. Fasting Blood Sugar

    blood sample

    Time frame: 4 week

  2. 2 hours Post Prandial Glucose

    blood sample

    Time frame: 4 week

  3. Serum Insulin

    blood sample

    Time frame: 4 week

  4. C Reactive Protein

    blood sample

    Time frame: 4 week

  5. Uric acid

    blood sample

    Time frame: 4 week

  6. Creatinine

    blood sample

    Time frame: 4 week

  7. Triglyceride

    blood sample

    Time frame: 4 week

  8. Cholesterol

    blood sample

    Time frame: 4 week

  9. Low Density Lipoprotein

    blood sample

    Time frame: 4 week

  10. High Density Lipoprotein

    blood sample

    Time frame: 4 week

  11. Aspartate Aminotransferase

    blood sample

    Time frame: 4 week

  12. Alanine Aminotransferase

    blood sample

    Time frame: 4 week

  13. weight

    Scale

    Time frame: 4 week

  14. Body Mass Index

    Body Mass Index

    Time frame: 4 week

  15. waist circumference

    Meter

    Time frame: 4 week

  16. hip circumference

    Meter

    Time frame: 4 week

  17. Systolic Blood Pressure

    Blood Pressure measurement by digital sphygmometer

    Time frame: 4 week

  18. Diastolic Blood Pressure

    Blood Pressure measurement by digital sphygmometer

    Time frame: 4 week

06

Study locations

2 sites
  • Shahid Motahhari Clinic, Shiraz University of Medical Sciences
    Shiraz, Fars, Iran, Islamic Republic of
  • Shiraz University of Medical Sciences
    Shiraz, Fars, Iran, Islamic Republic of
07

Registry details

Key details

Study ID
NCT03304938
Lead sponsor
Shiraz University of Medical Sciences
Responsible party
Mesbah Shams, MD (Associate professor of internal medicine and endocrinology, Shiraz University of Medical Sciences) — Principal investigator
First posted
Oct 9, 2017
Start date
Feb 1, 2018
Primary completion
Nov 1, 2018
Completion
Dec 1, 2018
Last update
Apr 8, 2019

Study contacts

Mesbah Shams, M.D.
study chair · Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion